Bioventix plc                                 
                            ("Bioventix" or the "Company")                         

                         Trading update and notice of results                      

    Bioventix plc (BVXP), a UK company specialising in the development and
    commercial supply of high-affinity monoclonal antibodies for applications in
    clinical diagnostics, announces a trading update following the year ended 30
    June 2015.

    As highlighted in the interim results, the core business remains robust and the
    board is pleased to report that revenues for the year are expected to be in
    excess of £4.2m (2014:£3.5m).  Given the relatively modest and fixed cost base,
    profits before tax will be significantly ahead of market expectations.

    The Company expects to announce its preliminary results for the year ended 30
    June 2015 on 5 October 2015.

    For further information please contact:

    Bioventix plc                                            Tel: 01252 728 001         
    Peter Harrison              Chief Executive Officer                                 
                                                                                        
    finnCap Ltd                                              Tel: 020 7220 0500         
    Geoff Nash/Simon Hicks      Corporate Finance                                       
    Steve Norcross              Corporate Broking                                       

    About Bioventix plc:

    Bioventix (www.bioventix.com) specialises in the development and commercial
    supply of high-affinity monoclonal antibodies with a primary focus on their
    application in clinical diagnostics, such as in automated immunoassays used in
    blood testing. The antibodies created at Bioventix are generated in sheep and
    are of particular benefit where the target is present at low concentration and
    where conventional monoclonal or polyclonal antibodies have failed to produce a
    suitable reagent. Bioventix currently offers a portfolio of antibodies to
    customers for both commercial use and R&D purposes, for the diagnosis or
    monitoring of a broad range of conditions, including heart disease, cancer,
    fertility, thyroid function and drug abuse. Bioventix currently supplies
    antibody products and services to the majority of multinational clinical
    diagnostics companies. Bioventix is based in Farnham, UK and its shares are
    traded on AIM under the symbol BVXP.